XML 26 R13.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Revenue from Contracts with Customers | 3 Months Ended
--- | ---
Mar. 31, 2018
Revenue from Contract with Customer [Abstract] |
Revenue from Contract with Customers | Revenue from Contracts with Customers. On January 1, 2018, we adopted ASU 2014-09, Revenue from Contracts with Customers (Topic 606) ("ASC 606"), and all subsequent ASUs that modified ASC 606, electing the modified retrospective approach. Results for reporting periods beginning after January 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and continue to be reported under ASC 605, Revenue Recognition (Topic 605). The adoption of ASC 606 did not have a material impact on the measurement or recognition of revenue in any period. As such, we did not record a cumulative adjustment to the opening equity balance of retained earnings as of January 1, 2018 under the modified retrospective method upon adoption. We have applied this guidance to contracts that were not completed at the date of initial application. In accordance with ASC 606, we recognize revenue when a customer obtains control of promised goods. The amount of revenue recognized reflects the consideration to which we expect to be entitled to receive in exchange for these goods. To achieve this core principle, we apply the following five steps:
1. | Identify the contract with the customer. A contract with a customer exists when (i) we enter into an enforceable contract with a customer that defines each party’s rights regarding the goods to be transferred and identifies the payment terms related to these goods, (ii) the contract has commercial substance and, (iii) we determine that collection of substantially all consideration for services that are transferred is probable based on the customer’s intent and ability to pay the promised consideration. We do not have significant costs to obtain contracts with customers. For commissions on product sales, we have elected the practical expedient to expense the costs as incurred if the amortization period would have been one year or less.
2. | Identify the performance obligations in the contract. Generally, our contracts with customers do not include multiple performance obligations to be completed over a period of time. Our performance obligations relate to delivering single-use medical products to a customer, subject to the shipping terms of the contract. Limited warranties are provided, under which we typically accept returns and provide either replacement parts or refunds. We do not have significant returns. We do not typically offer extended warranty or service plans.
3. | Determine the transaction price. Payment by the customer is due under customary fixed payment terms, and we evaluate if collectability is reasonably assured. None of our contracts as of March 31, 2018 contained a significant financing component. Further, the methodology for which we estimate and recognize variable consideration (e.g. rebates) is consistent with the requirements of ASC 606. Revenue is recorded at the net sales price, which includes estimates of variable consideration such as product returns, rebates, discounts, and other adjustments. The estimates of variable consideration are based on historical payment experience, historical and projected sales data, and current contract sales terms. Variable consideration is included in revenue only to the extent that it is probable that a significant reversal of the revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Taxes collected from customers relating to product sales and remitted to governmental authorities are excluded from revenues.
4. | Allocate the transaction price to performance obligations in the contract. We typically do not have multiple performance obligations in our contracts with customers. As such, we recognize revenue upon delivery of the product to the customer's control at contractually stated pricing.
5. | Recognize revenue when or as we satisfy a performance obligation. We satisfy performance obligations at a point in time upon either shipment or delivery of goods, in accordance with the terms of each contract with the customer. We do not have significant service revenue.
There were no changes in significant judgments that affect the determination of the amount and timing of revenue resulting from the adoption of the new guidance. In addition, there were no significant changes to our internal controls over financial reporting. As a result of the adoption of ASC 606, the allowance for sales returns has been prospectively reclassified from trade receivables to accrued expenses within the unaudited consolidated balance sheet as of March 31, 2018. Prior period balances remain unchanged. Disaggregation of Revenue The disaggregation of revenue is based on type of product and geographical region. For descriptions of our product offerings and segments, see Note 12 in our annual report on Form 10-K for the year ended December 31, 2017. The following table presents revenue from contracts with customers for the three months ended March 31, 2018 and 2017:
| Three months ended March 31, 2018 |  | Three months ended March 31, 2017
| United States |  | International |  | Total |  | United States |  | International |  | Total
Cardiovascular |  |  |  |  |  |  |  |  |  |  |
Stand-alone devices | 44,010 |  |  | 39,236 |  |  | 83,246 |  |  | 36,164 |  |  | 27,489 |  |  | 63,653 |
Custom kits and procedure trays | 22,318 |  |  | 10,954 |  |  | 33,272 |  |  | 21,466 |  |  | 7,408 |  |  | 28,874 |
Inflation devices | 7,668 |  |  | 14,751 |  |  | 22,419 |  |  | 7,975 |  |  | 10,532 |  |  | 18,507 |
Catheters | 15,270 |  |  | 18,595 |  |  | 33,865 |  |  | 15,129 |  |  | 15,047 |  |  | 30,176 |
Embolization devices | 5,033 |  |  | 7,554 |  |  | 12,587 |  |  | 5,541 |  |  | 6,986 |  |  | 12,527 |
CRM/EP | 8,838 |  |  | 1,628 |  |  | 10,466 |  |  | 9,747 |  |  | 1,270 |  |  | 11,017 |
Total | 103,137 |  |  | 92,718 |  |  | 195,855 |  |  | 96,022 |  |  | 68,732 |  |  | 164,754 |
Endoscopy |  |  |  |  |  |  |  |  |  |  |
Endoscopy devices | 6,918 |  |  | 262 |  |  | 7,180 |  |  | 6,095 |  |  | 220 |  |  | 6,315 |
Total | 110,055 |  |  | 92,980 |  |  | 203,035 |  |  | 102,117 |  |  | 68,952 |  |  | 171,069 |

X
- Definition Revenue from Contract with Customer [Text Block] + References No definition available. + Details
Name: | mmsi_RevenueFromContractWithCustomerTextBlock
Namespace Prefix: | mmsi_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenue from Contract with Customer [Abstract] + References No definition available. + Details
Name: | mmsi_RevenuefromContractwithCustomerAbstract
Namespace Prefix: | mmsi_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration